Spyre Therapeutics Inc (SYRE)

$41.25 -1.06 (-2.51%)
Market Cap 3.38B
Revenue (ttm) 0.00
Net Income (ttm) -155.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,410,500
Avg Vol 719,116
Day's Range N/A - N/A
Shares Out 78.54M
Stochastic %K 35%
Beta 3.09
Analysts Strong Sell
Price Target $60.78

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necros...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 5940
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
FoxyDreams
FoxyDreams Mar. 16 at 11:30 PM
/@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $NUAI $HURA $SYRE $FTRK ** on watch
0 · Reply
DwigtMcDichael
DwigtMcDichael Mar. 16 at 4:53 PM
$SYRE I like when my bios have news. This one is loaded all year
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Mar. 15 at 8:00 PM
$SYRE https://www.marketbeat.com/stocks/NASDAQ/SYRE/institutional-ownership/
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 3:11 PM
$SYRE Current Stock Price: $41.97 Contracts to trade: $40.0 SYRE Mar 20 2026 Call Entry: $1.10 Exit: $1.94 ROI: 77% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:17 PM
$SYRE Spyre Therapeutics (NASDAQ: SYRE) has surged nearly 63% over the past year, crushing the S&P 500. With a $757 million cash runway, six Phase 2 readouts ahead, and growing institutional backing, investors are watching closely to see if this inflammatory bowel disease biotech is just getting started. https://biotechhealthx.com/biotech-news/should-you-now-start-buying-spyre-therapeutics-syre-shares/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 27 at 7:00 PM
$SYRE Q4 '25 Earnings Results & Recap Spyre Therapeutics reported a net loss of $155.2M for the year ended December 31, 2025, with R&D expenses increasing 5% to $171.7M and G&A expenses rising 5% to $47.9M.
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 6:29 PM
Clinical breakthroughs sent $SYRE into a 1D parabolic move with RSI tagging 81. The 1W trend is dominant, but 4H and 30M CCI indicate extreme extension, making a STOCH cooling period likely. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 3:37 PM
Clinical breakthroughs sent $SYRE into a 1D parabolic move with RSI tagging 81. The 1W trend is dominant, but 4H and 30M CCI indicate extreme extension, making a STOCH cooling period likely. @DailyAnalysis
0 · Reply
PushHarder_
PushHarder_ Feb. 23 at 1:02 PM
$HLF $PRLD $HYMC $SYRE ’•’•’
0 · Reply
edvquye
edvquye Feb. 22 at 11:38 PM
$SYRE
0 · Reply
Latest News on SYRE
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Mar 17, 2026, 2:18 PM EDT - 3 days ago

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 11, 2026, 1:40 AM EDT - 10 days ago

Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Spyre Therapeutics Announces Grants of Inducement Awards

Mar 6, 2026, 4:05 PM EST - 14 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 4:05 PM EST - 24 days ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 19, 2026, 4:02 PM EST - 4 weeks ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Jan 12, 2026, 8:00 AM EST - 2 months ago

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Spyre Therapeutics: Validated Targets, Optimized Delivery

Jan 1, 2026, 4:36 AM EST - 2 months ago

Spyre Therapeutics: Validated Targets, Optimized Delivery

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:05 PM EST - 4 months ago

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Nov 4, 2025, 4:01 PM EST - 4 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Oct 24, 2025, 8:00 AM EDT - 5 months ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Oct 15, 2025, 4:15 PM EDT - 5 months ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Oct 13, 2025, 9:07 PM EDT - 5 months ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Oct 13, 2025, 4:01 PM EDT - 5 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Oct 5, 2025, 9:00 AM EDT - 5 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Intelligent Development Could Make Spyre Therapeutics Best In Show

Sep 18, 2025, 10:34 PM EDT - 6 months ago

Intelligent Development Could Make Spyre Therapeutics Best In Show

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 8, 2025, 4:05 PM EDT - 6 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:02 PM EDT - 8 months ago

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Jun 18, 2025, 2:58 PM EDT - 9 months ago

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Jun 17, 2025, 7:30 AM EDT - 9 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Jun 16, 2025, 4:05 PM EDT - 9 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025, 8:30 AM EDT - 10 months ago

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 11 months ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 5, 2025, 8:00 AM EDT - 11 months ago

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Mar 4, 2025, 4:51 AM EST - 1 year ago

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Feb 19, 2025, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Jan 13, 2025, 8:00 AM EST - 1 year ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 18, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Dec 4, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 3, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Dec 2, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Dec 2, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Dec 1, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Nov 29, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Nov 28, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 27, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Nov 26, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 5:11 PM EST - 1 year ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Nov 25, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 24, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Nov 22, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Nov 20, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Nov 18, 2024, 9:18 PM EST - 1 year ago

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

FoxyDreams
FoxyDreams Mar. 16 at 11:30 PM
/@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $NUAI $HURA $SYRE $FTRK ** on watch
0 · Reply
DwigtMcDichael
DwigtMcDichael Mar. 16 at 4:53 PM
$SYRE I like when my bios have news. This one is loaded all year
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Mar. 15 at 8:00 PM
$SYRE https://www.marketbeat.com/stocks/NASDAQ/SYRE/institutional-ownership/
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 3:11 PM
$SYRE Current Stock Price: $41.97 Contracts to trade: $40.0 SYRE Mar 20 2026 Call Entry: $1.10 Exit: $1.94 ROI: 77% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:17 PM
$SYRE Spyre Therapeutics (NASDAQ: SYRE) has surged nearly 63% over the past year, crushing the S&P 500. With a $757 million cash runway, six Phase 2 readouts ahead, and growing institutional backing, investors are watching closely to see if this inflammatory bowel disease biotech is just getting started. https://biotechhealthx.com/biotech-news/should-you-now-start-buying-spyre-therapeutics-syre-shares/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 27 at 7:00 PM
$SYRE Q4 '25 Earnings Results & Recap Spyre Therapeutics reported a net loss of $155.2M for the year ended December 31, 2025, with R&D expenses increasing 5% to $171.7M and G&A expenses rising 5% to $47.9M.
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 6:29 PM
Clinical breakthroughs sent $SYRE into a 1D parabolic move with RSI tagging 81. The 1W trend is dominant, but 4H and 30M CCI indicate extreme extension, making a STOCH cooling period likely. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 3:37 PM
Clinical breakthroughs sent $SYRE into a 1D parabolic move with RSI tagging 81. The 1W trend is dominant, but 4H and 30M CCI indicate extreme extension, making a STOCH cooling period likely. @DailyAnalysis
0 · Reply
PushHarder_
PushHarder_ Feb. 23 at 1:02 PM
$HLF $PRLD $HYMC $SYRE ’•’•’
0 · Reply
edvquye
edvquye Feb. 22 at 11:38 PM
$SYRE
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 22 at 4:56 PM
Clinical breakthroughs sent $SYRE into a 1D parabolic move with RSI tagging 81. The 1W trend is dominant, but 4H and 30M CCI indicate extreme extension, making a STOCH cooling period likely. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 21 at 8:26 PM
$SYRE 1W accumulation accelerates after positive trial data. 1D RSI is overbought, but 4H CCI and STOCH show sustained momentum. 30M volume confirms aggressive bidding as traders digest the narrowed Q4 fiscal loss. @DailyAnalysis
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 5:50 PM
$SYRE RSI: 80.94, MACD: 1.7168 Vol: 2.66, MA20: 34.45, MA50: 33.41 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Feb. 20 at 6:41 PM
Wells Fargo maintains Spyre Therapeutics $SYRE at Overweight and raises the price target from $40 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
inspector_gadget86
inspector_gadget86 Feb. 20 at 2:55 PM
$SYRE Reported $756.5 million in cash/marketable securities as of Dec 31, 2025, providing a runway into H2 2028
0 · Reply
Pika_Capital
Pika_Capital Feb. 20 at 2:51 PM
$SYRE beautiful action. One of the core positions
0 · Reply
StockConsultant
StockConsultant Feb. 19 at 2:13 PM
$SYRE Spyre Therapeutics stock, watch for a continuation breakout, target 41+ area at https://stockconsultant.com/?SYRE
0 · Reply
PatriciaWong158
PatriciaWong158 Feb. 18 at 1:32 PM
$SYRE Biotech microcap with funding uncertainty.
0 · Reply
ortega1963
ortega1963 Feb. 13 at 2:37 PM
$SYRE Breaking out
0 · Reply
ortega1963
ortega1963 Feb. 13 at 2:32 PM
$SYRE long
0 · Reply
StockConsultant
StockConsultant Feb. 13 at 1:22 PM
$SYRE Spyre Therapeutics stock, watch for a top of range breakout at https://stockconsultant.com/?SYRE
1 · Reply
OphirMedia
OphirMedia Feb. 13 at 2:15 AM
Checking the pulse on these names for the Friday close: $IRWD $SYRE $WOLF $APH $TTE. ​We’ve got a mix of high-growth biotech momentum, AI infrastructure, and a massive turnaround play. ​1️⃣ Is $IRWD really the best 'Fallen Angel' play right now? 2️⃣ Can $SYRE sustain this biotech run? 3️⃣ $WOLF vs. $APH – which one dominates the tech rotation?
0 · Reply